Tonix Pharmaceuticals Holding Corp. (TNXP) |
|
1.4 0.03 (2.19%)
|
08-14 12:33 |
|
Open: |
1.39 |
Pre. Close: |
1.37 |
|
High:
|
1.43 |
Low:
|
1.36 |
|
Volume:
|
2,690,783 |
Market Cap:
|
60(M) |
|
|
|
|
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.43 - 1.44 |
1.44 - 1.45 |
|
Low:
|
1.34 - 1.35 |
1.35 - 1.36 |
|
Close:
|
1.39 - 1.4 |
1.4 - 1.42 |
|
Technical analysis |
as of: 2022-08-12 4:25:56 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.14 One year: 2.61 |
| Support: |
Support1: 1.19 Support2: 0.99 |
| Resistance: |
Resistance1: 1.83 Resistance2: 2.24 |
| Pivot: |
1.63  |
| Moving Average: |
MA(5): 1.41  MA(20): 1.54
MA(100): 3.16 MA(250): 9.44 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 17.4 %D(3): 20.3 |
| RSI: |
RSI(14): 42.1 |
| 52-week: |
High: 24.95 Low: 0.46 |
| Average Vol(K): |
3-Month: 11,167 (K) 10-Days: 11,537 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TNXP ] has closed above bottom band by 16.8%. Bollinger Bands are 55.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 11 Aug 2022
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 204.6% in July - Defense World
Mon, 01 Aug 2022
TNXP, GOVX, VRAX stocks rally as New York calls outbreak public emergency (NASDAQ:TNXP) - Seeking Alpha
Sun, 31 Jul 2022
Tonix Pharmaceuticals (TNXP) Stock: Why It Fell 10.16% - Pulse 2.0
Fri, 29 Jul 2022
Thinking about buying stock in Intel Corp, Thermogenesis, SIGA Technologies, Tonix Pharmaceuticals, or Sunrun? - PR Newswire
Thu, 28 Jul 2022
TNXP gains on partnership to study monkeypox vaccine in H1 2023 (NASDAQ:TNXP) - Seeking Alpha
Wed, 27 Jul 2022
Tonix Pharmaceuticals (NASDAQ:TNXP) Raised to “Sell” at StockNews.com - Defense World
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
32 (M) |
| Shares Float |
19 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
9.6 (%) |
|
Shares Short
|
775 (K) |
|
Shares Short P.Month
|
1,560 (K) |
Stock Financials |
|
EPS
|
-7.51 |
|
EPS Est Next Qtl
|
-0.75 |
|
EPS Est This Year
|
-3.02 |
|
EPS Est Next Year
|
-2.48 |
|
Book Value (p.s.)
|
12.03 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-30.1 |
|
Return on Equity (ttm)
|
-51 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.09 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-86 (M) |
|
Levered Free Cash Flow
|
-101 (M) |
Stock Valuations |
|
PE Ratio
|
-0.19 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.11 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.52 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-10-31 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
